[ad_1]
The two companies announced on Monday that a COVID-19 vaccine jointly developed by Sanofi and GlaxoSmithKline has shown a strong immune response in early clinical trial results, allowing it to enter late-stage research.
France’s Sanofi and Britain’s GlaxoSmithKline (GSK) said a global Phase 3 trial will begin in the next few weeks, involving more than 35,000 adults. The goal is that the vaccine will be approved in the fourth quarter before it is initially hit in the first half of this year.
The delay was announced at the end of last year, When the two companies discussed their intentions to improve the effectiveness of shooting for the elderly.
The two companies said in December that early trials showed that the vaccine produced an “insufficient” immune response in people over 60, because the vaccine did not contain enough substances to trigger the production of anti-disease antibodies. The drugmaker said they plan to reformulate the vaccine and conduct more tests.
Since then, in the second phase of the study involving 722 volunteers, the COVID-19 vaccine candidate achieved a strong antibody-based immune system response in all adult age groups. This discovery was announced from COVID-Sanofi on the 19th.
Lens, Through the technological development of the two companiesCombining a spike protein-based antigen and an adjuvant, an adjuvant is a substance that enhances the immune system’s response to the presence of an antigen.
Sanofi’s executive vice president and global head Thomas Triomphe said in a statement that the latest data show that the vaccine has the potential to “solve this ongoing global public health crisis.”
Canada has reached an agreement for up to 72 million doses of the vaccine, pending approval by Health Canada.
Earlier this year, Sanofi also announced Invest to boost Canadian vaccine production, Has promoted the creation of hundreds of jobs and millions of dollars in research and development funds each year.
[ad_2]
Source link